The fourth follow-up QO qualified neuroimaging of the dopamine transporter as an enrichment biomarker for Parkinson’s Disease (PD) (20) and was preceded by two previous QA procedures—an initial QA procedure and a follow-up QA. Here, SLC6A3 is linked to Parkinson disease.